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The nucleocapsids of many plant viruses are signiﬁcantly more robust and protective of their RNA
contents than those of enveloped animal viruses. In particular, the capsid protein (CP) of the plant virus
Cowpea Chlorotic Mottle Virus (CCMV) is of special interest because it has been shown to spontaneously
package, with high efﬁciency, a large range of lengths and sequences of single-stranded RNA molecules.
In this work we demonstrate that hybrid virus-like particles, assembled in vitro from CCMV CP and a
heterologous RNA derived from a mammalian virus (Sindbis), are capable of releasing their RNA in the
cytoplasm of mammalian cells. This result establishes the ﬁrst step in the use of plant viral capsids as
vectors for gene delivery and expression in mammalian cells. Furthermore, the CCMV capsid protects the
packaged RNA against nuclease degradation and serves as a robust external scaffold with many
possibilities for further functionalization and cell targeting.
& 2013 Elsevier Inc. All rights reserved.Introduction
The use of animal virus-like particles (VLPs) as vectors for the
delivery of genes to mammalian cells has been explored for many
years and by a large variety of very different approaches (Schaffer
et al., 2008; Lavillette et al., 2001; Soong et al., 2000). In this paper
we examine the possibility of using a well-characterized plant RNA
virus for expression of heterologous genes in mammalian cells.
Unlike mammalian viruses—the majority of whose nucleocapsids
are enveloped by an extra layer of protection in the form of a viral
envelope—plant viruses are almost without exception “just”
genetic material (DNA or RNA) surrounded by a shell composed
of the capsid protein (CP). Because the viral genome is protected
only by this protein shell, the resulting nucleocapsid (nucleic acid
packaged inside a capsid) is signiﬁcantly more robust than its
counterpart in enveloped animal viruses.
Consider, for example, the “superfamily” of single-stranded
RNA viruses comprised of bromoviruses (infecting plants) and
alphaviruses (infecting animals), and whose members include
Cowpea Chlorotic Mottle Virus (CCMV) and Sindbis Virus (SINV),
respectively (Strauss and Strauss, 1994). The nucleocapsids of both
CCMV (Bancroft and Hiebert, 1967; Zhao et al., 1995; Fox et al.,
1998) and SINV (Wengler et al., 1982; Tellinghuisen et al., 1999;
Mukhopadhyay et al., 2002; Giocochea et al., 2007; Cheng and
Mukhopadhyay, 2011) have been reconstituted in vitro from
puriﬁed components. However, the nucleocapsids of CCMV arell rights reserved.
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, Mexico.much more stable in solution than those of SINV. Furthermore, in
contrast to SINV nucleocapsids that have evolved to depend on
their viral envelope for protection against nucleases, CCMV capsids
protect their RNA content against digestion.
Equally important, CCMV capsid protein has been shown to be
capable of packaging, via spontaneous in vitro self-assembly, a
wide range of non-viral cargo, including: heterologous RNAs
(Hiebert et al., 1968; Bancroft et al., 1969; Rao, 2006), synthetic
anionic polymers (Douglas and Young, 1998; Hu et al., 2008;
Brasch and Cornelissen, 2012, Cadena-Nava et al., 2011), miner-
alized salts (Douglas and Young, 1998), negatively charged colloi-
dal particles such as gold nanoparticles (Chen et al., 2006) and oil-
in-water nanoemulsion droplets (Chang et al., 2008), ﬂuorescent
proteins (Minten et al., 2009), and pH-controlled chromophores
(Brasch et al., 2011). In addition, by functionalizing and chemically
modifying their capsids, closely-related plant viruses like Cowpea
Mosaic Virus (CPMV) have been used for targeting of and uptake
by speciﬁc mammalian cells for imaging and drug delivery (Destito
et al., 2007; Gonzales et al., 2009; Yildiz et al., 2011; Steinmetz,
2010; Wu et al., 2012). Similarly, MS2 VLPs containing a variety of
drugs, siRNAs, and toxins have been conjugated with peptide
ligands and shown to produce selective cytotoxicity in cancer cells
(Ashley et al., 2011).
Plant-derived VLPs, however, have not been used for direct gene
delivery and expression, although a recent study (Li et al., 2012)
reports the transfection of tobacco mosaic virus (TMV) virions into
HeLa cells with the resulting expression of TMV capsid protein.
Interestingly, high-level expression of mammalian genes in plant
hosts, mediated by Agrobacterium plasmids containing the
translation-enhancement elements from messenger RNAs of the
plant virus CPMV, has been demonstrated for various target proteins
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baculovector system has also been effectively used for expression of
mammalian genes in a wide variety of insect and mammalian hosts
(Chen et al., 2011), but unlike the system we describe here it cannot
be reconstituted in vitro and must be prepared by recombinant
plasmid engineering in cell culture.
There have been no attempts to use a spherical plant viral
capsid to deliver heterologous genes for expression in mammalian
cells, even though there are several independent demonstrations
of the internalization of plant virus by such cells. Examples include
the membrane-protein-mediated uptake of CPMV by mouse vas-
cular endothelial cells (Koudelka et al., 2009) and the uptake of
brome mosaic virus (BMV) by human bronchial epithelial cells
(Jung et al., 2011).
The possibility of uptake and release of the contents of a plant
capsid in a mammalian cell has been suggested in the case of red
clover necrotic mosaic virus (RCNMV) (Lockney et al., 2011).
In particular, capsids of puriﬁed virus loaded with doxorubicin
were functionalized with HeLa cell-targeting peptides, and the
survivability of HeLa cells overlaid by them shown to decrease
with doxorubicin concentration. While disassembly of the capsids
in the HeLa cells was not directly established, doxorubicin was
argued to be released by the same divalent cation-controlled
mechanism as known to occur with RCNMV RNA in plant
cell hosts.
In light of there being no direct demonstration of spherical
plant viruses disassembling and thereby releasing their contents in
animal cells, we consider here the question: Can heterologous
genes in spherical plant VLPs be made available to a mammalian
cell and their protein products synthesized?
In answering this question, and thereby providing a new
platform for gene delivery to mammalian cells, we take advantage
of many unique in vitro reconstitution properties of the spherical
plant virus, CCMV. In particular—in contradistinction to the CPMV
and RCNMV examples mentioned above—the puriﬁed capsid
protein of CCMV is capable of efﬁciently packaging a large range
of RNA lengths and sequences, including arbitrary transgenes of
interest. If these in vitro synthesized VLPs can be shown to
disassemble and release their RNA contents in mammalian cells,
then the stage is set for functionalizing the capsids to target those
cells in vivo.
Our strategy is the following. We reconstitute in vitro a well-
characterized VLP consisting of a reporter ssRNA molecule pack-
aged inside a CCMV capsid. To this end, we designed a SINV-
derived defective interfering RNA (DI[EYFP], 1800 nt: Fig. 1iii),
which upon transcription produces the mRNA for expression of
high levels of enhanced yellow ﬂuorescent protein (EYFP). Theψ
3’UTR5’UTR
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Fig. 1. Schematics of the relevant RNA reagents. (i) Wt SINV genome. The blocks
labeled NS and S are the open reading frames coding for the replicase proteins and
the structural proteins ([CP] and [GPs]). Ψ denotes the packaging signal, a sub-
sequence in NS responsible for the preferential packaging of the RNA by its capsid
protein. The hook-arrow denotes the promoter sequence controlling transcription
of the downstream (structural, S) genes. (ii) GP-replicon RNA. Same as i, except for
deletion of the CP gene. (iii) DI[EYFP] RNA. Derived from i upon deletion of most of
the NS ORF and replacement of the structural genes (S ORF) with EYFP ORF. The Ψ
signal is not present, but the cis-acting elements—the 5′ and 3′ untranslated
regions (UTRs) needed for replication by the NS complex—are retained.VLPs containing DI[EYFP] are transfected into a monolayer of baby
hamster kidney (BHK) cells. The machinery for the transcription
and replication of the DI[EYFP] RNA is supplied by a SINV-like
particle (GP-Rep vector: Fig. 1ii) providing the replicase proteins
that will efﬁciently replicate the DI[EYFP] RNA molecule if and only
if the encapsidated DI[EYFP] RNA is released from the VLPs upon
internalization. Therefore, the expression of EYFP in vector-
infected, VLP-transfected, cells can report on the successful release
of the encapsidated RNA for transcription, replication and
translation.
Fig. 1 shows schematically the coding and regulatory sequences
of the full SINV RNA genome (i), highlighting the two open reading
frames (ORFs) coding for the nonstructural (NS) genes (RNA-
dependent RNA polymerase) and structural (S) genes (capsid
protein (CP) and membrane glycoproteins (GP)). Also shown is
the SINV-derived glycoprotein “replicon” (GP-Rep) RNA (ii),
obtained by deleting the CP gene in the full SINV genome (See
Methods). A defective-interfering (DI) RNA molecule (iii) is derived
from it by deleting most of the nonstructural ORF and replacing
the structural genes by the EYFP gene (see METHODS).Results and discussion
VLP synthesis and characterization
As described in the Methods section, DI[EYFP] RNA and an
excess of CCMV CP are subjected to the standard protocol for
in vitro reconstitutions of RNA and CCMV CP. Basically, they are
incubated together at neutral pH and then dialyzed against pH
4.8 buffer solution.
The resulting mixture was run in a 1% agarose electrophoresis
gel, and ethidium bromide (EtBr) staining revealed no bands
associated with free (unpackaged) RNA. Rather, the only band
observed was one corresponding to VLPs (Fig. 2B, VLP [−]) which
are resistant to RNase digestion (Fig. 2B, VLP [þ]). Note that this
RNase treatment was sufﬁcient for complete digestion of naked
RNA (Fig. 2B, RNA). Comparing the band intensity with lanes
containing a set of CCMV standards of known concentration
(Fig. 2A) showed that the assembled VLPs contained a concentra-
tion of RNA equal to 18 ng/ml. Furthermore, the VLPs were homo-
geneous (see, however, discussion below TEM data) and had
electrophoretic mobilities corresponding to well-formed VLPs.
The assembly mix was imaged by negative-stain transmission
electron microscopy (TEM). The images showed spherical VLPs
(Fig. 3, micrograph) with a distribution of diameters corresponding
to roughly equal numbers of “pseudo T¼2” and T¼3 capsids,
overlapping the range of wt CCMV virions (Fig. 3, histogram)—in
agreement with what was previously found for packaging of
2000-nt RNA into CCMV VLPs (Cadena-Nava et al., 2012).
CCMV VLPs can release their RNA content in the cytoplasm of
mammalian cells
Having characterized the plant virus VLPs containing DI[EYFP]
RNA, we then transfected mammalian cells with them, using
Lipofectamine-2000 (see METHODS). The transfected cells were
incubated for 30 min to allow for internalization of the VLPs and
for release of their RNA in the cytoplasm. At this point, GP-Rep
vector was added at a multiplicity of infection (MOI) of 100 in
order to produce a high copy number of EYFP mRNA from DI[EYFP]
RNAs that had been released from their CCMV capsids and
successfully delivered to the cytoplasm. The intracellular ﬂuores-
cence signal generated by the subsequent translation of this
ampliﬁed mRNA into EYFP could then be used to report on the
level of VLP delivery and the release of its RNA.
+ +
_ _
1 2 3
E
tB
r s
ta
in
 in
te
ns
ity
 (A
U
)
0
0.1
0.2
0.3
0.4
0.5
0.6
VLP RNA CCMV
0 5 10 15 20
CCMV
linear fit
VLP -
VLP+
conc of RNA (ng/  L)μ
Fig. 2. (A) Quantiﬁcation of VLPs by densitometry. The densitometry plot quantiﬁes the amount of RNA packaged in VLPs by measuring the EtBr ﬂuorescence intensity from
CCMV bands of known concentration. (B) Agarose gel electrophoresis of synthesized VLPs, naked DI[EYFP] 1800 nt-RNA, and CCMV particle standards with known
concentrations. Electrophoresis was carried out in a 1% agarose gel and in virus buffer (VB: see Methods); the gel was stained with EtBr. (þ) and (−) designations refer to the
presence or absence of RNase A. The CCMV standards prepared by adding 10 μL of CCMV at concentrations of 93 (1), 69.8 (2), and 46.5 (3) ng/μL, respectively, correspond to
concentrations of RNA (within the virions) of 20, 15, and 10 ng/μL.
Fig. 3. Characterization of the VLP Size Distribution. Left: Distributions of diameters of VLPs (cross-hatched) and of wt CCMV virions (grey). Right: A negative-stain TEM
micrograph of the VLPs assembled from CCMV CPþDI[EYFP] RNA. Scale bar¼100 nm.
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transfected by Lipofectamine-2000 into BHK cells under similar
conditions. In addition, a sample consisting of “naked” VLPs (i.e.,
VLPs in ﬁnal assembly buffer without Lipofectamine) was incu-
bated with BHK cells.
The transfected cells were imaged by ﬂuorescence microscopy
to estimate the number of cells positive for EYFP. The number of
EYFP-expressing cells was also quantiﬁed by ﬂow cytometry; the
transduction efﬁciencies are shown as a function of RNase treat-
ment in Fig. 4A.
The number of ﬂuorescent cells is lower (by a factor of 5) in the
case of VLP transfection than for RNA. Two explanations are
plausible for this observation: either CCMV VLPs have a lower
transfection efﬁciency than their corresponding RNA content, or
not all of the VLPs disassemble to make their RNA content
available for transcription, replication and translation. The second
scenario—that only about a ﬁfth of the VLPs are releasing theirgene cargo, as opposed to 5 times fewer VLPs being transfected
than RNAs—is consistent with experiments in which equal num-
bers of the same VLPs and RNA molecules were manually micro-
injected—rather than transfected—into the same BHK cells, and the
VLPs were found to give rise to a factor of 5 fewer ﬂuorescent cells
(data not shown).
CCMV VLPs remain intact prior to cell entry and protect their RNA
content against RNase digestion
Two variations on the transfection procedure involving RNase A
were carried out in parallel to gain further information about the
physical state of the VLPs during transfection. They are referred to
as “RN1” and “RN2” and are described below:
RN1: Before the initial equilibration with Lipofectamine-2000,
RNase A was added to both the packaged and naked RNA samples.
This digestion step was designed to remove all naked full-length
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(reported by EYFP production) generated by the VLPs did not
come from trace amounts of unpackaged RNA or from RNA that
escaped from the VLPs during transfection. We observed (Fig. 4B iv
and vi) essentially identical transduction efﬁciencies for VLPs with
and without RNase digestion, indicating that unpackaged RNA
was not involved. We also observed the complete absence of
EYFP transduction in the digested naked RNA sample (see
Fig. 4Biii), conﬁrming that the concentration of RNase A used
was adequate for complete removal of all naked full-length RNA in
solution.
RN2: RNase A was added immediately after the addition of
Lipofectamine. This digestion step was designed to test whether
Lipofectamine-2000 is capable of protecting unpackaged RNA
against RNase A digestion. Our results show (see Fig. 4) that
adding RNase A at this step of the transfection procedure results
in a large attenuation of the transduction activity of the naked RNA
while having no effect on that of the VLPs, indicating again that
VLPs are being transfected as intact capsids.
The intact state of the plant viral capsids, even after RNase
treatment in the absence and presence of Lipofectamine, is
only one measure of their robustness. Another is their “shelf-life”
between synthesis and transfection: in the experiments describedFig. 4. VLPs can release their RNA content into the cytoplasm of transfected cells.
(A) Determination of Transduction Efﬁciency by Flow Cytometry. The left bars show
the fractions of positive cells for duplicate sets of transfections of VLPs (red) and
naked RNA (black) that were not treated with RNase A. The middle bars show the
effect of adding RNase A after mixing with Lipofectamine-2000 (RN2, see text). The
right bars show the result of incubation with RNase A before addition of
Lipofectamine (RN1). From the precision of the cytometry measurements (0.002),
an application of the Student t-test shows that the differences between the RNA
and VLP measurements are signiﬁcant with a probability of at least 95%.
(B) Fluorescence micrographs of representative ﬂuorescent cell densities for each
scenario. Panel (iv) in (B) shows that transfected VLPs can deliver their RNA content
into the cytoplasm of mammalian cells, where the RNA is involved in downstream
processes, as is the case for the naked RNA control (B(i)). As expected, the naked
VLPs overlaid on cells without any Lipofectamine could not transduce cells with
EYFP (data not shown).above, for example, the VLPs were left for 1 week at 4 °C before
being subjected to RNase treatment and transfection.Conclusions
We have shown that plant VLPs formed in vitro from CCMV
capsid protein and several-thousand-nt-long RNA: (1) are resistant
to RNase; (2) can be transfected into mammalian cells, and
(3) disassemble in these cells, resulting in the expression of the
target transgene.
This demonstration establishes that plant virus capsids—here
CCMV—are capable of protecting their RNA contents outside the
cell, and yet making them available in the intracellular environ-
ment of mammalian cells. We have chosen the CP as well as the
RNA of a super-family of plus-strand RNA viruses like CCMV and
SINV—as opposed to minus-strand or retro RNA viruses—in order
to avoid the complications of needing to package directly the
delicate RNA-dependent RNA polymerase or reverse transcriptase
proteins themselves, Further, with plus-strand viruses, all of the
nucleic acid replication takes place in the cytoplasm rather than
requiring trafﬁcking of RNA into and out of the host cell nucleus. In
addition, utilizing the DI[EYFP] RNA in conjunction with GP-Rep
vector infection, we are able to exploit the powerful messenger
RNA ampliﬁcation scheme unique to plus-strand RNA viruses
(Strauss and Strauss, 1994; Frolov et al., 1996). More explicitly,
upon release from its VLP each DI[EYFP] RNA is not only tran-
scribed into EYFP mRNA suitable for translation, but is also
replicated by the RNA-dependent RNA polymerase (supplied by
the GP-Rep vector) into many copies, each of which can in turn be
transcribed again and used in the translation of the reporter EYFP.
It is this enhancement that signiﬁcantly increases the sensitivity
for detecting RNA release from the VLPs in the cytoplasm.
These studies were undertaken to demonstrate that nucleocap-
sids of plant viral capsid protein—prepared as nuclease-resistant
closed shells—are capable of making available heterologous RNA
content to mammalian cells, and that RNA genes in this form can be
expressed. Disassembly of these VLPs is most likely driven by their
binding to ribosomes, as has been demonstrated in studies of
bromoviruses (Roenhorst et al., 1989) and alphaviruses (Singh and
Helenius, 1992). Here we have used transfection of the VLPs to
provide a “proof of principle” demonstration of RNA release and
expression. The results of this work can now be directly combined
with functionalization of the capsid protein for targeting and uptake
by mammalian cells (Destito et al., 2007; Gonzales et al., 2009;
Yildiz et al., 2011; Steinmetz, 2010; Wu et al., 2012; Koudelka et al.,
2009; Jung et al., 2011; Lockney et al., 2011), thereby facilitating the
use of reconstituted plant viral capsids for gene delivery.Materials and methods
Constructs and reagents
Di[EYFP]–RNA
The DI[EYFP] construct was the result of (1) deletion of the
region spanning BamHI and BspEI restriction sites on the NS ORF
of SINV cDNA, and (2) replacement of the S ORF with nuclear EYFP
ORF, using standard molecular biology protocols. The resulting
plasmid—after linearization—was used as the template for in vitro
transcription using Ambion Sp6 mMessage mMachine in vitro
transcription kit. The RNA was puriﬁed with a Qiagen mini RNeasy
kit, and quantiﬁed by UV absorption at 260 nm.
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First, two constructs, GP-Rep and DHBB plasmids, were pre-
pared: GP-Rep was made by deleting the CP gene from the
structural ORF in the SINV cDNA while DHBB was made by
deleting the region between BamHI and BspEI sites on the NS
ORF of SINV cDNA. These constructs were made into correspond-
ing RNA transcripts, using in vitro transcription (see above). Next,
the two RNAs were cotransfected into BHK cells using electro-
poration protocol. The vector particles were harvested from the
medium on top of transfected cells after 24 h.
CCMV CP puriﬁcation
CCMV was puriﬁed from infected California cowpea plant
(Vigna ungiculata cv Black Eye) (Bancroft, 1970) and CP was
isolated as described previously (Cadena-Nava et al., 2011;
Annamalai and Rao, 2005). SDS-PAGE and MALDI-TOF were
employed to ascertain that the puriﬁed protein was intact.
VLP assembly reactions
DI[EYFP] RNA was packaged by CCMV CP at a CP:RNA mass
ratio of 6.5:1 to ensure complete RNA packaging. Assembly was
carried out by mixing CP and RNA in buffer B (1 M NaCl, 20 mM
Tris-HCl pH 7.2, 1 mM EDTA, 1 mM DTT and 1 mM PMSF), followed
by dialysis against RNA assembly buffer (RAB: 50 mM NaCl, 10 mM
KCl, 5 mM MgCl2, 1 mM DTT, 50 mM Tris-HCl pH 7.2) for 4 h,
followed by dialysis against virus buffer (VB: 0.1 M sodium acetate,
1 mM EDTA, pH 4.8) for 16 h, all at 4 °C. Free (excess) CP was
removed by washing the sample with VB in a 100 kDa Amicon
centrifugal ﬁltration unit at 3000 G at 4 °C.
Electron microscopy characterization of VLPs
A 6 μl aliquot of the ﬁnal assembly mixture was applied to a
glow-discharged copper grid (400-mesh) that previously had been
coated with Parlodion and carbon. The mix was spread onto the
grid for 1 min, blotted with Whatman ﬁlter paper and then stained
with 6 μL of 1% uranyl acetate for 1 min. Excess stain was removed
by blotting with ﬁlter paper. The samples were stored overnight in
a desiccator and analyzed with a JEM 1200-EX transmission
electron microscope operated at 80 keV and equipped with a
wide-angle (top mount) BioScan 600 W 1×1 K2 pixel digital
camera. The reported average diameter of VLPs is that of the
geometric mean of two orthogonal measurements of the capsids
obtained with ImageJ (U.S. National Institutes of Health) software
from recorded images.
Preparation of BHK cell culture
Prior to transfection, BHK-21 cells were grown as monolayers
on 6-well plates at 37 °C in a CO2 incubator. EMEM (ATCC)
supplied with 10% (v/v) FCS and Penicillin-streptomycin was used
to grow and maintain cells.
Lipofectamine transfections
Monolayers of BHK cells were grown on six-well plates to 90%
conﬂuence. Transfection with Lipofectamine-2000 was carried out
following a standard protocol normally used for the transfection of
nucleic acids. Brieﬂy, the protocol consisted of the following (5) steps:(1) An aliquot of VLPs (or naked RNA) containing 1 μg of DI[EYFP]
RNAwas diluted into Opti-MEM to 300 μl for each transfection.
Similarly, 3 μl of Lipofectamine-2000 was diluted into 300 μl
Opti-MEM and the dilutions were incubated at room tempera-
ture for 5 min.(2) The two diluted reagents were mixed and (RNA/VLPþLipofec-
tamine) complexes were allowed to form by incubating at
room temperature for 30 min.(3) The cells were washed with 1× nuclease-free PBS before
overlaying the transfectant onto the cells, followed by incuba-
tion at 37 °C in a CO2 incubator with occasional shaking to
distribute the transfectant evenly on the cells.(4) After 30 min of incubation, a 150-mL aliquot of GP-Rep vector
at an MOI of >100 was added to the cells in order to supply the
replication machinery necessary for EYFP production. Longer
incubation times did not enhance the transduction yield (data
not shown).(5) After 4 h the transfectant/inoculum was removed and the cells
were gently washed twice with pre-warmed 1× PBS and 1 ml
of 2% FCS mediumwas overlaid on the cells. The cells were left
overnight at 37 °C in a CO2 incubator.RNase A assays
All RNase A digestion steps were carried out using 0.2 ng/μl
RNase A for 30 min at room temperature. For digestions that were
performed during the transfection protocol (i.e. scenarios RN1 and
RN2), this concentration of RNase A was maintained throughout
each subsequent step of the protocol. These conditions were found
to be sufﬁcient to remove all full-length RNA band intensity from
the agarose gel assay (Fig. 2B, RNA panel) as well as completely
destroy the transfection efﬁciency of naked RNA by Lipofectamine-
2000 (Fig. 4A and 4Biii, vi).
Flow cytometry
Twenty-four hour post-transfection, the cells were washed
with 1× PBS, trypsinized, and resuspended in 1× PBS buffer with
2% FCS at a density of 3×106 cells/ml. Analysis was performed
using a Becton Dickinson SORP BD LSRII Analytic Flow Cytometer
equipped with a 488-nm blue laser for excitation of EYFP. Yellow-
green YFP ﬂuorescence was collected after a 530/30 bandpass
ﬁlter. FACSDIVa software was used to control the parameters
during the run and to analyze collected data.Acknowledgments
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